PI3Kδ抑制剂罗吉诺利西布 (IOA-244) 保持T细胞的功能和活动
Elise Solli1,2, Alessio Bevilacqua3, Mathias Wenes4,5
1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Norway.
Molecular oncology
|January 22, 2026
概括
罗吉诺利西布有效地向白血病细胞,像idelalisib一样,但更好地保留T细胞功能. 这种PI3K抑制剂可能为血液癌症治疗提供更安全的替代方案.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 酸酸3-激酶抑制剂 (PI3Ki) 在血液癌症中显示出有前途.
- 严重的与免疫相关的不良影响限制了目前的PI3Ki发展.
- 需要改进安全配置文件的新型PI3Ki.
研究的目的:
- 评估罗吉诺利西布 (IOA-244) 和伊德拉利西布在免疫和白血病细胞上的体外影响.
- 比较这两种PI3K抑制剂的疗效和安全性.
- 确定与目前的PI3Ki具有降低免疫毒性的潜在替代品.
主要方法:
- 在体外对罗吉诺利西布和伊德拉利西布的评估.
- 对慢性淋巴细胞白血病细胞的影响的评估.
- 对T细胞信号传递,激活,增殖和细胞毒性功能的分析.
主要成果:
- 罗吉诺利西布和伊德拉利西布都抑制了白血病细胞的信号传递和活力.
- 这两种药物都在T细胞中表现出针对性PI3K抑制.
- 罗吉诺利西布保留了T细胞功能,包括细胞毒性活性和分化,与idelalisib不同.
- 伊德拉利西布在降低调控T细胞频率方面显示出更大的效力,但影响了CD8+T细胞功能.
结论:
- 罗吉诺利西布是针对白血病细胞的有效PI3K抑制剂.
- 罗吉诺利西布保留了关键的T细胞功能,与idelalisib不同.
- 罗吉诺利西布代表了一种有前途的替代PI3K抑制剂,在血液癌症中具有潜在的安全性.
相关概念视频
Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
B Cell Activation and Differentiation
16.2K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
16.2K
T Cell Types and Functions
2.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.2K
Dipeptidyl Peptidase 4 Inhibitors
614
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
614
T Cell Activation and Clonal Selection
14.8K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.8K
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K


